Tags

Type your tag names separated by a space and hit enter

Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
Ophthalmic Res. 2017; 58(1):8-14.OR

Abstract

BACKGROUND

The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO).

METHODS

Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection.

RESULTS

BCVA in both groups at each follow-up were significantly increased compared to baseline with no statistical difference between the groups. Ozurdex and ranibizumab successfully reduced CMT at each follow-up. Both CRVO and BRVO patients had significant between-group differences in the mean number of injections. Among the CRVO patients, IOP in the Ozurdex group was significantly increased compared to baseline and the ranibizumab group at 1, 2, and 3 months postinjection.

CONCLUSIONS

Intravitreal injection of Ozurdex and ranibizumab can effectively control ME secondary to RVO and increase a patient's BCVA. The advantages of Ozurdex are fewer injections and longer efficacy, while the advantages of ranibizumab include fewer side effects.

Authors+Show Affiliations

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28334720

Citation

Gu, Xiaoya, et al. "Intravitreal Dexamethasone Implant Versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population." Ophthalmic Research, vol. 58, no. 1, 2017, pp. 8-14.
Gu X, Yu X, Song S, et al. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Ophthalmic Res. 2017;58(1):8-14.
Gu, X., Yu, X., Song, S., & Dai, H. (2017). Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Ophthalmic Research, 58(1), 8-14. https://doi.org/10.1159/000458534
Gu X, et al. Intravitreal Dexamethasone Implant Versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Ophthalmic Res. 2017;58(1):8-14. PubMed PMID: 28334720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. AU - Gu,Xiaoya, AU - Yu,Xiaobing, AU - Song,Shuang, AU - Dai,Hong, Y1 - 2017/03/24/ PY - 2016/08/11/received PY - 2017/01/30/accepted PY - 2017/3/24/pubmed PY - 2017/9/2/medline PY - 2017/3/24/entrez KW - Dexamethasone KW - Macular edema KW - Ranibizumab KW - Retinal vein occlusion SP - 8 EP - 14 JF - Ophthalmic research JO - Ophthalmic Res VL - 58 IS - 1 N2 - BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection. RESULTS: BCVA in both groups at each follow-up were significantly increased compared to baseline with no statistical difference between the groups. Ozurdex and ranibizumab successfully reduced CMT at each follow-up. Both CRVO and BRVO patients had significant between-group differences in the mean number of injections. Among the CRVO patients, IOP in the Ozurdex group was significantly increased compared to baseline and the ranibizumab group at 1, 2, and 3 months postinjection. CONCLUSIONS: Intravitreal injection of Ozurdex and ranibizumab can effectively control ME secondary to RVO and increase a patient's BCVA. The advantages of Ozurdex are fewer injections and longer efficacy, while the advantages of ranibizumab include fewer side effects. SN - 1423-0259 UR - https://www.unboundmedicine.com/medline/citation/28334720/Intravitreal_Dexamethasone_Implant_versus_Intravitreal_Ranibizumab_for_the_Treatment_of_Macular_Edema_Secondary_to_Retinal_Vein_Occlusion_in_a_Chinese_Population_ L2 - https://www.karger.com?DOI=10.1159/000458534 DB - PRIME DP - Unbound Medicine ER -